anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Adiposity can be measured using BMI (which is based on weight and height) as well as indices of abdominal adiposity. We examined the association between BMI and waist-to-height ratio (WHtR) within and across populations of different world regions and quantified how well these two metrics discriminate between people with and without hypertension.
METHODS: We used data from studies carried out from 1990 to 2023 on BMI, WHtR and hypertension in people aged 20-64 years in representative samples of the general population in eight world regions. We graphically compared the regional distributions of BMI and WHtR, and calculated Pearson's correlation coefficients between BMI and WHtR within each region. We used mixed-effects linear regression to estimate the extent to which WHtR varies across regions at the same BMI. We graphically examined the prevalence of hypertension and the distribution of people who have hypertension both in relation to BMI and WHtR, and we assessed how closely BMI and WHtR discriminate between participants with and without hypertension using C-statistic and net reclassification improvement (NRI).
FINDINGS: The correlation between BMI and WHtR ranged from 0·76 to 0·89 within different regions. After adjusting for age and BMI, mean WHtR was highest in south Asia for both sexes, followed by Latin America and the Caribbean and the region of central Asia, Middle East and north Africa. Mean WHtR was lowest in central and eastern Europe for both sexes, in the high-income western region for women, and in Oceania for men. Conversely, to achieve an equivalent WHtR, the BMI of the population of south Asia would need to be, on average, 2·79 kg/m2 (95% CI 2·31-3·28) lower for women and 1·28 kg/m2 (1·02-1·54) lower for men than in the high-income western region. In every region, hypertension prevalence increased with both BMI and WHtR. Models with either of these two adiposity metrics had virtually identical C-statistics and NRIs for every region and sex, with C-statistics ranging from 0·72 to 0·81 and NRIs ranging from 0·34 to 0·57 in different region and sex combinations. When both BMI and WHtR were used, performance improved only slightly compared with using either adiposity measure alone.
INTERPRETATION: BMI can distinguish young and middle-aged adults with higher versus lower amounts of abdominal adiposity with moderate-to-high accuracy, and both BMI and WHtR distinguish people with or without hypertension. However, at the same BMI level, people in south Asia, Latin America and the Caribbean, and the region of central Asia, Middle East and north Africa, have higher WHtR than in the other regions.
FUNDING: UK Medical Research Council and UK Research and Innovation (Innovate UK).
Early Intervention Programa (IG): Patients assigned to the intervention group after the randomization were offered an immediate appointment. Patients, who voluntarily accepted, were attended by 2 rheumatologists. The rheumatologists acted as principal care providers in regular visits, home visits and phone contacts. The visits were structured following specific proceedings for the different diagnoses based on previously demonstrated approaches. Such protocols included education and promotion of independence, pharmacological and no pharmacological treatment, and timing of diagnostic tests in a stepwise manner. The program also incorporated administrative duties such as the prescription of medication for the patients. Patients were seen as often as necessary according to the medical rheumatologist decision (until the episode of disability was medically resolved).
INTRODUCTION: Cytomegalovirus (CMV)-infection and reactivation remain a relevant complication after liver transplantation (LT). The recipient and donor serum CMV-IgG-status has been established for risk stratification when choosing various pharmaceutical regimens for CMV-prophylaxis in the last two decades. However, factors influencing course of CMV-infection in LT remain largely unknown. In this study, the impact of immunosuppressive regimen was examined in a large cohort of patients.
METHODS: All patients that underwent primary LT between 2006 and 2018 at the Charité-Universitaetsmedizin, Berlin, were included. Clinical course as well as histological and laboratory findings of patients were analyzed our prospectively maintained database. Univariate and multivariate regression analysis for impact of variables on CMV-occurrence was conducted, and survival was examined using Kaplan-Meier analysis.
RESULTS: Overall, 867 patients were included in the final analysis. CMV-infection was diagnosed in 325 (37.5%) patients after transplantation. Significantly improved overall survival was observed in these patients (Log rank = 0.03). As shown by correlation and regression tree classification and regression tree analysis, the recipient/donor CMV-IgG-status with either positivity had the largest influence on CMV-occurrence. Analysis of immunosuppressive burden did not reveal statistical impact on CMV-infection, but statistically significant inverse correlation of cumulative tacrolimus trough levels and survival was found (Log rank < .001). Multivariate analysis confirmed these findings (p = .02).
DISCUSSION: CMV-infection remains of clinical importance after LT. Undergone CMV-infection of either recipient or donor requires prophylactic treatment. Additionally, we found a highly significant, dosage-dependent impact of immunosuppression (IS) on long-term outcomes for these patients, underlying the importance of minimization of IS in liver transplant recipients.
Adequate neutral detergent insoluble fiber (NDF) content in the total diet can improve intake efficiency, prevent rumen disorders, and enhance the health and performance of feedlot-finished beef cattle. We hypothesized that an increase in dietary fiber levels would decrease the productive performance but increase the economic performance of young bulls in confinement. Thus, it was aimed to evaluate the effect of increasing fiber levels on feed intake, wastage, and productive and economic performance of Nellore young bulls finished in confinement. We used 20 Nellore cattle, non-castrated males, 30 months old, and average body weight (BW) of 416.35 ± 2.2 kg distributed in a completely randomized design, kept in individual stalls. Animals were divided into four treatments consisting of four levels of neutral detergent insoluble fiber (NDF) (25%, 30%, 35%, and 40% NDF) in total DM. Nutrient intake, feed conversion, feed waste, body weight (BW) at slaughter, total weight gain (TWG), average daily gain (ADG), hot carcass weight (HCW), and carcass yield (CR) were evaluated. In addition, economic parameters (revenue, food expenses, and gross margin) were calculated and compared. The dry matter (DMI), organic matter (OMI), crude protein (CPI), and ether extract (EEI) intakes showed quadratic behavior. The DMI maximum estimated was 28.5% NDF in the diet. The NDF and ADF intakes showed a positive linear effect and the starch intake had a negative linear effect. There was a significant positive linear effect (P < 0.05) for the variables total mixed ration (TMR) offered and daily and total RTM intake. Minimum RTM wastage was estimated with a diet containing 30% NDF. The maximum points for BW at slaughter, HCW, and ADG were 29.9%; 29.6%, and 25% NDF, respectively. The costs of concentrate and silage showed a positive linear behavior, as did the ADG costs and the carcass equivalent cost (P < 0.05). The maximum point of the revenue estimate (US$/animal) was 29.9% of NDF, 26.1% of NDF for the total expenditure on food (US$/animal), and 32.5% of NDF for the gross margin (U$/animal). In conclusion, the animals fed a 30% NDF diet showed the best performance and economics, in addition to less food waste. We recommend 25 to 32.5% of NDF in the diet to obtain maximum productive and economic performance when finishing Nellore young bulls in confinement.
Patients with Non-Muscle Invasive Bladder Cancer who are receiving intravesical treatments are eligible to participate in this study. Participants will be asked to complete the Zung Self-Rating Anxiety Scale and Zung Self-Rating Depression Scale prior to each induction intravesical treatment. During the 6-week induction intravesical treatment, participants will also be given a daily mood dairy to complete. Urine Specimens will be collected prior to each induction intravesical treatment and at each 3-month cystoscopy appointment during the treatment course. An at home urine collection may occur 6 hours post intravesical treatment. Research Blood Samples will be collected prior to the first induction intravesical treatment, prior to the fourth intravesical treatment, and prior to each 3-month follow-up cystoscopy as indicated by the participant's treatment course. Participants will be asked to complete the Zung Self-Rating Anxiety Scale and Zung Self-Rating Depression Scale prior to each 3-month follow-up cystoscopy during the treatment course. A 3-week daily mood diary will be completed by participants during the 3-week intravesical maintenance treatment. Participants will be given a daily mood diary to complete between the 3-month follow-up cystoscopy appointments.
Morbidly obese subjects (body mass index greater than 40) will be given propofol for induction of general anesthesia. Plasma samples will be taken to ascertain drug concentration over time.
A biodegradable lens-shaped patch useful for healing and treatment of ocular conditions is disclosed. The patch is formed from a biodegradable carrier which carries amniotic extract and/or placental extract. The biodegradable carrier may be a collagen material. The lens-shaped patch may be shaped in the form of a conventional contact lens and s applied to a corneal surface to enhance healing of corneal injuries. After a certain period of time, the patch dissolves on its own and it need not be removed from the eye by a clinician. The degradation of the patch is controlled by the degree of cross-linking in the carrier material.
FIELD: organic chemistry, chemistry of high-molecular compounds, biochemistry. SUBSTANCE: method involves oxidation of dextran with sodium periodate, precipitation with ethanol, conjugation of obtained dialdehyde dextran with isoniazid and reduction of Schiff's base formed with sodium boron hydrode. Before precipitation with ethanol dialysis of dialdehyde dexran is carried out. Conjugation is carried out by addition of isoniazid as a dry substance at amount providing its concentration 0.3 mole/l. Dialysis of conjugate solution is carried out before its precipitation with ethanol. Invention can be used in development of new antituberculosis drugs of enhanced effectiveness. EFFECT: increased content of isoniazid, high purity and stability of product.
Patients will receive vorinostat by mouth once a day for 4 weeks. Treatment may repeat every 4 weeks for as long as benefit is shown. Patients will be evaluated for 4 weeks and every 3 months thereafter.
Participants allocated to this arm follow are requested to inform the sponsor of any side effects up to 2 months after prescription of the anti-dementia drug. If so, they will have their treatment adjusted according to the serum level. Participants in the intervention arm not experiencing side effects will have their treatment adjusted after 6 months based upon serum level of the drug in question.
FIELD: medicine. SUBSTANCE: after operative intervention perforated veins are bandaged at area of trophic disorders. Necrotic tissue of trophic ulcers are evaporated with the help of carbon dioxide laser, defocused beam at wavelength 10.6 μm at density 40mWt/cm 2  and exposition 3-4 s/сm 2  being used. Three days after rejection of coagulation film takes place the whole operation zone is affected by defocused beam of He-Ne laser at wavelength 0.63 μm, density 20 mWt/сm 2 , exposition being 180-300 s said process is carried out to complete epithelization. Bandage of 5 % actovegine ointment is applied after each of seances. Simultaneously actovegine solution is injected intravenously within 8 days, scheme of injection being given in specification. EFFECT: decreases treatment time.
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

Adverse events reported by 2% or more of patients treated with fenofibrate (and greater than placebo) during the double-blind, placebo-controlled trials, regardless of causality, are listed in Table 1 below. Adverse events led to discontinuation of treatment in 5.0% of patients treated with fenofibrate and in 3.0% treated with placebo. Increases in liver function tests were the most frequent events, causing discontinuation of fenofibrate treatment in 1.6% of patients in double-blind trials.

Table 1. Adverse Reactions Reported by 2% or More of Patients Treated with Fenofibrate and Greater than Placebo During the Double-Blind, Placebo-Controlled Trials

Urticaria was seen in 1.1% vs. 0%, and rash in 1.4% vs. 0.8% of fenofibrate and placebo patients respectively in controlled trials.
The invention relates to the field of pharmaceutical preparations, and discloses a local anesthetic external preparation and a method for improving the stability of the local anesthetic external preparation. The local anesthetic external preparation comprises a local anesthetic and a packaging material, wherein the packaging material is a polyester/aluminum/cycloolefin composite aluminum film. The polyester/aluminum/cycloolefin composite aluminum film is a novel composite low-absorption packaging material. The method for improving the stability of the local anesthetic pharmaceutical preparation is to package the local anesthetic pharmaceutical preparation by adopting a polyester/aluminum/cycloolefin composite aluminum film as a packaging material. The method of the invention does not need to add any antioxidant or nitrogen filling and vacuum pumping operations, and has simple and convenient operation. Experiments show that the polyester/aluminum/cycloolefin composite aluminum film is used for packaging the topical preparation of the local anesthetic, so that the content of the active drug in the preparation can be ensured, and the stability of the local anesthetic can be effectively improved.
This Potassium Chloride Injection, is a sterile, nonpyrogenic, highly concentrated, ready-to-use, solution of Potassium Chloride, USP in Water for Injection, USP for electrolyte replenishment in a single dose container for intravenous administration. It contains no antimicrobial agents.

This VIAFLEX Plus plastic container is fabricated from a specially formulated polyvinyl chloride (PL 146 Plastic). Exposure to temperatures above 25°C/77°F during transport and storage will lead to minor losses in moisture content. Higher temperatures lead to greater losses. It is unlikely that these minor losses will lead to clinically significant changes within the expiration period. The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container may leach out certain of its chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the plastic container materials.
The study is a prospective randomized open label multicenter study with a registry follow up in which patients with out of hospital cardiac arrest without ST-elevation on their first ECG will be randomized to either a strategy of immediate coronary angiography (treatment group) with possible coronary intervention or a strategy of delayed coronary angiography (control group). The study will include in total 1006 patients with Restoration of Spontaneous Circulation (ROSC). Randomization will be done via a web-based module after ECG is taken at the first medical contact but no later than after arrival at the emergency room. Coronary angiography should be performed within 120 minutes from randomization in the immediate angiography group. In the delayed angiography group, angiography with possible coronary intervention will be performed at the discretion of the interventional cardiologist and should preferably not be performed until three days after the cardiac arrest. This strategy is in accordance with standard practice. In case of recurrent chest pain, ST elevation, circulatory instability or cardiogenic shock, cross over to early angiography may occur. The quality of life and health economics will be evaluated at 6 months. The patients will undergo extensive neurocognitive tests and health instruments, these will be analyzed and presented.
Copolymers having tertiary amine groups and composed of 16 - 43% methyl methacrylate, 25 - 54% dimethylamino ethyl methacrylate and 12 - 52% octadecyl methacrylate are particularly useful as hair treating resins with conventional carriers and additives. The copolymers can be crosslinked by up to 0.15 by an unsaturated agent to produce preferred copolymers used in wavesetting lotions in amounts of 1 - 3%. Such copolymers can also be partially or wholly quaternized by a quaternizing agent. Those copolymers not crosslinked are particularly useful as hair lacquers, especially in aerosol sprays in amounts of 1 - 4%. The molecular weight for the subject copolymers average 10,000 - 1,500,000 and copolymerization can be effected in a solvent with a catalyst wherein the reaction mixture is heated for about 6 to 24 hours at about 80 DEG C. When applied to the hair, the amount of lotion or lacquer used can be 10 - 100 cc. and the treated hair is rolled. After treatment, the hair holds its shape well and is easy to comb.
In 2018, 46363 new cases of lung cancers have been diagnosed in France. It is the second most frequent cancer in men and the third most frequent cancer in women. It is the deadliest cancer in men and second deadliest cancer in women with 33117 deaths in 2018. The gold standard treatment is lobectomy with lymph node dissection in patients with a resectable tumor. The main surgical approach has long been conventional thoracotomy. It is associated with prolonged post-operative pain and discomfort because of rib spreading which injures the intercostal nerve and a costo-transverse disjunction. Moreover, in patients with narrowed intercostal space or restrictive syndrome, cher is a high risk of rib fracture associated. Alternative surgical approaches have been developed to reduce the pain and discomfort during a lobectomy. Minimally invasive approaches are mainly represented by video-assisted thoracic surgery (VATS) and robotic-assisted thoracic surgery (RATS). These approaches are characterized by the use of an endoscope during the whole procedure associated with specific instruments and the absence of rib spreading. With these technique, a similar disease-specific long-term survival is obtained compared to conventional thoracotomy. These techniques also reduce post-operative complications, post-operative acute and chronic pain and improve the quality of life. The discomfort and the decrease in quality of life comes from the pain related to the incision but could also come from the postural dysfunction , more frequent and severe after conventional thoracotomy. The physiopathology behind this postural dysfunction are not well known but seem to be related to partially to the mechanical alteration of the rib cage and partially and because of a mechanical dysfunction related to the diaphragm following the surgery. The rib cage is an important element of postural stability. The diaphragm has a key role in both breathing and posture. Alterations of these structures dedicated to stability and ventilation are potentially associated with central mechanisms which end up in an adaptation of posture-respiratory coupling. By comparing conventional thoracotomy and VATS, it has been shown that lobectomy by VATS is associated with less disruption in posture and posture-respiratory coupling compared to thoracotomy. But no data hast yet compared RATS and conventional thoracotomy. The investigators hypothesized that RATS would cause less disruption in the postural alignment, in the perception of verticality and posture-respiratory coupling index (in static position and by walking) compared to conventional thoracotomy. In this context, the investigators aim to compare the effects of conventional thoracotomy with RATS on the rib cage and the posture-respiratory coupling.
Subjects received one of the four regimens over a four day treatment period. Regimen E = 5 mg ACM-001.1 and placebo BID for four days.
Hepatotoxicity, manifested as increases in ALT, aspartate aminotransferase (AST) and bilirubin, occurred in patients who received pazopanib tablets. This hepatotoxicity can be severe and fatal. Patients older than 65 years are at greater risk for hepatotoxicity [see Use in Specific Populations (8.5)]. Transaminase elevations occur early in the course of treatment; 92% of all transaminase elevations of any grade occurred in the first 18 weeks.

In the randomized RCC trial (VEG105192), ALT > 3 x ULN occurred in 18% and ALT > 10 x ULN occurred in 4% of the 290 patients who received pazopanib tablets. Concurrent elevation in ALT > 3 x ULN and bilirubin > 2 x ULN in the absence of significant alkaline phosphatase > 3 x ULN occurred in 2%. In the monotherapy trials, 2 patients died with disease progression and hepatic failure.

In the randomized STS trial (VEG110727), ALT > 3 x ULN occurred in 18% and ALT > 8 x ULN occurred in 5% of the 240 patients who received pazopanib tablets. Concurrent elevation in ALT > 3 x ULN and bilirubin > 2 x ULN in the absence of significant alkaline phosphatase > 3 x ULN occurred in 2%. One patient died of hepatic failure.

Monitor liver tests at baseline; at Weeks 3, 5, 7, and 9; at Month 3 and Month 4; and then periodically as clinically indicated. Increase to weekly monitoring for patients with elevated ALT until ALT returns to Grade 1 or baseline. Withhold pazopanib tablets and resume at reduced dose with continued weekly monitoring for 8 weeks, or permanently discontinue with weekly monitoring until resolution based on severity of hepatotoxicity [see Dosage and Administration (2.2)].

Gilbert's Syndrome

Pazopanib tablets is a uridine diphosphate (UDP)-glucuronosyl transferase 1A1 (UGT1A1) inhibitor. Mild, indirect (unconjugated) hyperbilirubinemia may occur in patients with Gilbert's syndrome  [see Clinical Pharmacology (12.5)]. In patients with only a mild indirect hyperbilirubinemia known as Gilbert's syndrome, manage elevation in ALT > 3 x ULN per the recommendations outlined for isolated ALT elevations  [see Dosage and Administration (2.2)].

Concomitant Use of Simvastatin

Concomitant use of pazopanib tablets and simvastatin increases the risk of ALT elevations [see Drug Interactions (7.3)]. Insufficient data are available to assess the risk of concomitant administration of alternative statins and pazopanib tablets.
NAs combined with peginterferon are used for 12-24 weeks, followed by peginterferon α-2b. The Maximum course is 96 weeks. Follow-up period is 144 weeks.
Vaccine formulations comprising polyglycerol polyricinoleate (PGPR) are disclosed. Certain disclosed exemplary vaccine formulations comprised an aqueous phase comprising inactivated bacteria and/or viruses, and/or bacterial and/or viral antigens. One particular embodiment comprised an inactivated H9N2 PGPR emulsion-based vaccine for day-old chicks. Disclosed PGPR-based vaccine formulations can be administered alone, or in combination with or as a composition including a second standard fast release vaccine. Disclosed vaccines delay antigen release, and therefore delay an immune response in a subject receiving the vaccine, typically by 7 - 35 days. The present invention also concerns a method for vaccinating a subject, such as poultry or fish, with disclosed vaccine formulations, as well as a method for making PGPR-based vaccine formulations.